FAScinate Therapeutics Completes Part 1a of Phase 2 Study of Company's Parkinson’s Disease Drug Candidate "KM-819" Read Now >
Thursday, January 12, 2023 / PRWeb
The latest updates on drug candidate KM-819.
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of Company’s Parkinson’s Disease Treatment with Approval from U.S. Food and Drug AdministrationRead Now >
Tuesday, November 23, 2021 / BioSpace
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of Company’s Parkinson’s Disease Treatment with Approval from U.S. Food and Drug AdministrationRead Now >
Wednesday, November 17, 2021 / PRWeb
FDA Approval Sought to Begin Phase 2 Trial of KM-819Read Now >
Wednesday, November 17, 2021 / Parkinson's News Today
FAScinate Therapeutics Inc. Submits Investigational New Drug (IND) Application for Phase 2 Clinical Studies of Company's New Parkinson's Disease TreatmentRead Now >
Friday, November 5, 2021 / FAScinate Therapeutics
Kainos Medicine Reaches Milestone in bringing “KM-819” Treatment for Parkinson‘s Disease to MarketRead Now >
Monday, January 7, 2019 / Senior Health News